

Resource Summary Report

Generated by [RRID](#) on Aug 3, 2026

A20

RRID:CVCL_1940

Type: Cell Line

Proper Citation

BCRJ Cat# 0030, RRID:CVCL_1940

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1940

Proper Citation: BCRJ Cat# 0030, RRID:CVCL_1940

Description: Cell line A20 is a Cancer cell line with a species of origin *Mus musculus* (Mouse)

Sex: Sex unspecified

Disease: Mouse reticulum cell sarcoma

Defining Citation: [PMID:310843](#), [PMID:22400032](#), [PMID:28902524](#), [PMID:31220119](#)

Comments: Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981)., Part of: ENCODE project mouse cell lines.

Category: Cancer cell line

Organism: *Mus musculus* (Mouse)

Name: A20

Synonyms: A-20

Cross References: BTO:BTO_0001930, CLO:CLO_0001564, CLO:CLO_0050194, EFO:EFO_0005285, ATCC:TIB-208, BCRC:60556, BCRJ:0030, BioSample:SAMN11397658, ChEMBL-Cells:ChEMBL3307765, ChEMBL-Targets:ChEMBL613850, CLS:305263, ENCODE:ENCBS119ENC, ENCODE:ENCBS431JNZ, GEO:GSM1014167, Lonza:743, PubChem_Cell_line:CVCL_1940, RCB:RCB2745, TKG:TKG 0571, TOKU-E:459, Ubigen:YC-C061, Wikidata:Q54606424

ID: CVCL_1940

Vendor: BCRJ

Catalog Number: 0030

Record Creation Time: 20220427T215105+0000

Record Last Update: 20260802T005646+0000

Ratings and Alerts

No rating or validation information has been found for A20.

No alerts have been found for A20.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 36 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Pizzo ME, et al. (2025) Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA. Science (New York, N.Y.), 389(6760), eads3204.

Luo S, et al. (2025) TCL1A in naïve B cells as a therapeutic target for type 1 diabetes. EBioMedicine, 113, 105593.

Petkov V, et al. (2025) ISCOM-type matrix from beta-escin and glycyrrhizin saponins. Heliyon, 11(2), e41935.

Hesterberg RS, et al. (2025) Lymphoma accelerates T cell and tissue aging. Cancer cell.

Guruprasad P, et al. (2025) Manufacturing of CRISPR-edited primary mouse CAR T cells for cancer immunotherapy. Nature protocols.

Kim HY, et al. (2024) Specific targeting of cancer vaccines to antigen-presenting cells via an endogenous TLR2/6 ligand derived from cysteinyl-tRNA synthetase 1. Molecular therapy : the journal of the American Society of Gene Therapy, 32(10), 3597.

He MY, et al. (2024) GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. Leukemia, 38(10), 2210.

Halász H, et al. (2024) Cooperation of Various Cytoskeletal Components Orchestrates Intercellular Spread of Mitochondria between B-Lymphoma Cells through Tunnelling Nanotubes. Cells, 13(7).

Xue G, et al. (2024) Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy. Cancer cell.

Heiser RA, et al. (2024) Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity. *Molecular cancer therapeutics*, 23(1), 68.

Yang Y, et al. (2024) The regulatory relationship between NAMPT and PD-L1 in cancer and identification of a dual-targeting inhibitor. *EMBO molecular medicine*, 16(4), 885.

Middelburg J, et al. (2023) The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent. *Cell reports*, 42(12), 113516.

Emrich SM, et al. (2023) Orai3 and Orai1 mediate CRAC channel function and metabolic reprogramming in B cells. *eLife*, 12.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. *Cancer research communications*, 3(4), 576.

Suzuki K, et al. (2023) Anti-PD-1 antibodies recognizing the membrane-proximal region are PD-1 agonists that can down-regulate inflammatory diseases. *Science immunology*, 8(79), eadd4947.

Madarász T, et al. (2023) Molecular Relay Stations in Membrane Nanotubes: IRSp53 Involved in Actin-Based Force Generation. *International journal of molecular sciences*, 24(17).

Zeyn Y, et al. (2023) Transcriptional Targeting of Dendritic Cells Using an Optimized Human Fascin1 Gene Promoter. *International journal of molecular sciences*, 24(23).

Miller CL, et al. (2022) Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression. *Cell chemical biology*, 29(3), 451.

Lu H, et al. (2022) Butyrate-producing *Eubacterium rectale* suppresses lymphomagenesis by alleviating the TNF-induced TLR4/MyD88/NF- κ B axis. *Cell host & microbe*, 30(8), 1139.

Mulgaonkar A, et al. (2022) ImmunoPET Imaging with ⁸⁹Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 28(22), 4907.